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Interleukin-21 (IL-21) plays important roles in regulating the immune response. IL-21 receptor (IL-21R)
mRNA is expressed at a low level in human resting T cells but is rapidly induced by mitogenic stimulation. We
now investigate the basis for IL21R gene regulation in T cells. We found that the 80 to 20 region critically
regulates IL-21R promoter activity and corresponds to a major DNase I-hypersensitive site. Electrophoretic
mobility shift assays, DNA affinity chromatography followed by mass spectrometry, and chromatin immuno-
precipitation assays revealed that Sp1 binds to this region in vitro and in vivo. Moreover, mutation of the Sp1
motif markedly reduced IL-21R promoter activity, and Sp1 small interfering RNAs effectively diminished
IL-21R expression in activated T cells. Interestingly, upon T-cell receptor (TCR) stimulation, T cells increased
IL-21R expression and Sp1 protein levels while decreasing Sp1 phosphorylation. Moreover, phosphatase
inhibitors that increased phosphorylation of Sp1 diminished IL-21R transcription. These data indicate that
TCR-induced IL-21R expression is driven by TCR-mediated augmentation of Sp1 protein levels and may partly
depend on the dephosphorylation of Sp1.
The interleukin-21 receptor (IL-21R) is a type I cytokine
receptor that is selectively expressed in lymphoid tissues, par-
ticularly by T, B, and NK cells (35, 38). IL-21R is most similar
to the IL-2 receptor  chain and the IL-4 receptor  chain (35,
38, 39), and correspondingly, IL-21 is most similar to IL-2,
IL-4, and IL-15 (38). Like IL-2, IL-4, IL-7, IL-9, and IL-15, the
receptor for IL-21 also contains the common cytokine receptor
 chain (c), and IL-21 signals in part through the activation of
Jak1 and Jak3 (2, 11, 24, 35).
IL-21 is produced by activated CD4 T cells (38, 39), and
corresponding to the expression of its receptor, IL-21 has ac-
tions on T, B, and NK cells. It enhances the proliferation of
both anti-CD3 activated thymocytes and peripheral T cells (16,
38), and it also acts synergistically with IL-7 or IL-15 to en-
hance CD8 T-cell proliferation (38, 57). IL-21 can promote
NK cell maturation from bone marrow progenitors and acti-
vate the cytolytic activity of peripheral NK cells, and it can
reduce IL-15-induced expansion of resting NK cells (16, 38),
although IL-21R/ mice have normal NK cell development
(37). IL-21 can augment B-cell death in vitro (31, 36) and in
vivo (36), but it also promotes the differentiation of B cells into
postswitch and plasma cells and is critical for antigen-specific
immunoglobulin (Ig) production in vivo (36, 37). IL-21R/
mice exhibited normal lymphocyte development but abnormal
Ig production, with reduced serum levels of IgG1 and IgG2b
but elevated IgE in response to antigen (37). Correspondingly,
IL-21 can inhibit antigen-induced IgE production (48). IL-
21R/ IL-4/ double knockout mice exhibit a severely
impaired IgG response as well as diminished IgE levels, indi-
cating that these two cytokines cooperatively regulate Ig pro-
duction (37). In addition to its physiological roles in lymphoid
biology, IL-21 has antitumor actions as well that correlate with
its ability to activate NK and cytotoxic CD8 T cells and to
enhance gamma interferon production by these cells (29, 47,
52, 57). Given the range of actions of IL-21 and its importance
in regulating the immune system, we investigated the molecu-
lar mechanism involved in IL21R gene regulation.
MATERIALS AND METHODS
Cell culture. Human peripheral blood (PB) lymphocytes were isolated from
normal donors by Ficoll density gradient centrifugation. T cells were purified by
negative selection (Pan T-cell isolation kit, Miltenyi Biotec, Auburn, CA) and
cultured at 37°C in RPMI 1640 medium supplemented with 10% fetal bovine
serum, 2 mM L-glutamine, 100 U/ml penicillin G, and 100 g/ml streptomycin.
Jurkat E6.1 cells (American Type Culture Collection, Manassas, VA) were
cultured in the same medium. Molt-3 cells (American Type Culture Collection)
were cultured in RPMI 1640 medium supplemented with 10% fetal bovine
serum, 2 mM GlutaMAX-1, 1 mM sodium pyruvate, 100 U/ml penicillin G, and
100 g/ml streptomycin.
Real-time PCR analysis. Total RNA was extracted using TRIzol (Invitrogen,
Carlsbad, CA). First-strand cDNA was made from 2 g of total RNA using
random hexamers and Omniscript reverse transcriptase (QIAGEN, Valencia,
CA), following the manufacturer’s suggested protocol. Quantitation of specific
mRNAs and 18S rRNA (as a control) was performed by real-time PCR using the
7900H sequence detection system (Applied Biosystems, Foster City, CA).
cDNAs were amplified using the TaqMan universal PCR master mix (Applied
Biosystems). The primers and probes used to detect human IL-21R, Sp1, and 18S
rRNA are as follows: IL-21R forward primer (5-TGTGGAGGCTATGGA
AGAAGATATG-3), reverse primer (5-GTGCACCCACCCATTTCTTG-3),
and probe (5-6-carboxyfluorescein [FAM]-CGGTTCTTCATGCCCCTGTAA
AGGG-6-carboxytetramethylrhodamine [TAMRA]-3); Sp1 forward primer
(5-CAGCTTCAGGCTGTTCCAAACT-3), reverse primer (5-CTGCCAACT
GACCTGTCCATT-3), and probe (5-FAM-TGGTCCCATCATCATCCG
GACACC-TAMRA-3); and 18S rRNA forward primer (5-TTCGGAACT
GAGGCATGAT-3), reverse primer (5-TTTCGCTCTGGTCCGTCTTG-3),
and probe (5-FAM-CGCCGCTAGAGGTGAAATTCTTGGACC-TAMRA-3).
5 RACE. Total RNA was isolated from activated human PB T cells, and rapid
amplification of 5 cDNA ends (5 RACE) was performed with a GeneRACER
kit (Invitrogen). A “RACER 5 primer” complementary to the RNA oligonu-
cleotide sequence and a gene-specific primer (GSP) complementary to IL-21R
cDNA (either GSP1, 5-GAGGAGGGAGACACTTCTTGAGT-3, or GSP2,
5-ACTGTCCTGAGCAGGTCACAGTC-3) were used in the PCR. The
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“RACER 5 nested primer” and either IL-21R GSP2 or GSP3 (5-CGGCTT
GATGCTCTCAGCCAGGA-3) were then used in a second, nested PCR. The
PCR product was subcloned into pCR4-TOPO vector with a TOPO TA cloning
kit (Invitrogen), and the nucleotide sequence was determined.
DNase I hypersensitivity assay. DNase I hypersensitivity assays were per-
formed as described previously (17). Briefly, Molt-3 cells were activated with
10 ng/ml of phorbol 12-myristate 13-acetate (PMA) plus 1 g/ml of ionomycin
for 4 h at 37°C. The nuclear pellet of the cells was digested with DNase I. The
purified genomic DNA was digested with NdeI (7617 and 6809) and BglI
(8118 and 3147) and Southern blotted (Nytran Plus, Schleicher & Schuell,
Keene, NH) using random primer-labeled probe 1 (6331 to 6754) and probe
2 (1051 to 1352) and Quickhyb solution (Stratagene, La Jolla, CA).
Restriction enzyme accessibility assay. A restriction enzyme accessibility assay
was performed as described previously (8). Briefly, human PB T cells were
activated with plate-bound anti-CD3 (2 g/ml) and 1 g/ml of anti-CD28 for 4 h,
followed by digestion with 5 U of BstEII for 10 min at 37°C. Two micrograms of
the DNA was digested with 10 U of StuI for 2 h at 37°C. Following blunting of
the DNA ends with Klenow, the DNA was ligated to a universal linker (34). The
cleavage sites were detected by PCR (34 cycles) with linker primer and a down-
stream antisense GSP (from 58 to 80, 5-GAGCTTACGGTCACTCAG
CAGAG-3). 32P-labeled downstream antisense primer (from 39 to 62,
5-CAGAGAGACGCCAGTGGGTCTGTC-3) was added to the PCR for the
last two cycles, and the PCR products were separated on polyacrylamide gels,
visualized by autoradiography, and quantitated using a PhosphorImager.
IL-21R luciferase reporter assays. The 5 regulatory region of the IL21R gene
from 2300 to 350 was subcloned between the BglII and XhoI polylinker sites
in the pREP4 luciferase reporter vector (27). Site-directed mutagenesis or de-
letion of the IL-21R61 to32 region were performed using a QuickChange kit
(Stratagene).
Molt-3 cells were transfected using DEAE-dextran with 10 g of the reporter
construct plasmid and 40 ng of pREP7 renilla luciferase vector as a transfection
efficiency control. After 24 h, cells were stimulated with medium alone or PMA
and ionomycin (PI). Luciferase activity was measured (18) after 18 h.
Transient transfection of normal murine splenic T cells was performed by
electroporation, as described previously (18). Preactivated murine splenic T cells
were mixed with 30 g of the IL-21R promoter reporter plasmid and 500 ng of
pREP7 renilla luciferase vector. After electroporation, cells were cultured for
3 h, and then half of the cells were stimulated with anti-CD3 plus anti-CD28.
After 18 h, the cells were harvested and analyzed for luciferase activity.
EMSAs and Western blotting. Nuclear extracts were prepared as described
previously (25) from untreated naı¨ve T cells or PI-activated T cells, and 10 g of
nuclear extracts and 20,000 cpm of 32P-labeled probe were used in electro-
phoretic mobility shift assays (EMSAs). For competition and supershift assays,
before adding the labeled probe, either excess unlabeled oligonucleotides or
antibodies to Sp1 or Sp3 (Upstate Biotechnology, Lake Placid, NY) or Sp2 or
Sp4 (Santa Cruz Biotechnology, Santa Cruz, CA) were preincubated with the
nuclear extracts. Recombinant Sp1 was from Sigma-Aldrich (St. Louis, MO), and
Sp3 was from Upstate Biotechnology.
Nuclear extracts (15 g) were resolved on 8% Novex Tris-glycine gel or 8%
NuPAGE Tris-acetate gel (Invitrogen) and blotted onto Immobilon-P mem-
branes (Millipore Corporation, Bedford, MA). The membranes were then blot-
ted with anti--tubulin (Santa Cruz Biotechnology) as a control or with anti-Sp1
FIG. 1. TCR-induced IL-21R expression in human T lymphocytes. Jurkat cells (A), Molt-3 cells (B), or purified human PB T cells (C) were
cultured in the presence of 10 ng/ml PMA plus 1 g/ml ionomycin for the indicated times. Human PB T cells were also cultured in the presence
of 2 g/ml anti-CD3 plus 1 g/ml anti-CD28 antibody, as indicated (D). Human PB T cells were also incubated for 2 h with actinomycin D
(10 g/ml) or cycloheximide (10 g/ml) with or without anti-CD3/anti-CD28 (E). Total RNA was isolated from cells, and first-strand cDNA was
synthesized. IL-21R mRNA levels were quantitated by real-time PCR and normalized to the level of 18S rRNA. For each sample, the bar
represents induction (n-fold) compared with no treatment. Values are means  standard errors of the mean (SEM) of results from three
experiments.
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and anti-Sp3 and developed by SuperSignal West Pico Chemiluminescent Sub-
strate (Pierce, Rockford, IL).
DNA affinity chromatography and mass spectrometry. DNA affinity chroma-
tography was performed as described previously (55). Briefly, the protein binding
site was concatemerized by a self-priming PCR technique using a wild-type
sequence (5-bio-CCCAGCTGCGGGTGGGCGGGGCTGGCGGGG-3) or a
similar mutant oligonucleotide (5-biotin-CCCAGCTGCGGGGTTGCGGGG
CTGGCGGGG-3). Six milligrams of nuclear extract from PI-activated human
PB T cells was incubated with streptavidin-conjugated biotinylated PCR product.
The bound proteins were eluted with binding buffer containing 600 mM KCl and
then dialyzed at 4°C overnight. The final eluate was resolved by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and silver stained. The
bands enriched with wild-type oligonucleotides were identified by liquid chro-
matography mass spectrometry (LC-MS) and matrix-assisted laser desorption
ionization–time of flight (MALDI-TOF) (Lerner Research Institute, Mass Spec-
trometry Laboratory for Protein Sequencing, the Cleveland Clinic Foundation,
Cleveland, Ohio).
Small interfering RNA (siRNA)-based inhibition. Purified human PB T cells
were transfected using the human T cell Nucleofector kit (Amaxa, Gaithersburg,
MD) with 100 nM siSp1, siSp3 (siGENOME SMARTpool siRNA, Dharmacon,
Lafayette, CO), or siControl (Dharmacon). Since the transfection efficiency in
human primary T cells was only 30 to 40%, we cotransfected the cells with
pEYFP-N1 (BD Clontech, Franklin Lakes, NJ), which expresses enhanced yel-
low fluorescent protein (YFP). After culturing in antibiotic-free medium for
36 h, cells positive for YFP were isolated by cell sorting and cultured in medium
alone or stimulated with anti-CD3 plus anti-CD28. After 2 h of incubation, total
RNA was extracted and analyzed by quantitative real-time PCR.
ChIP. Chromatin immunoprecipitation (ChIP) assays were performed as de-
scribed previously (27). Human PB T cells were activated with anti-CD3 plus
anti-CD28 for 2 h, followed by cross-linking with formaldehyde. Immunoprecipi-
tations were performed with 6 g of anti-Sp1 (Upstate Biotechnology) or normal
rabbit IgG (Santa Cruz Biotechnology) conjugated to Dynabeads protein A
(Dynal Biotech, Brown Deer, WI). Immunoprecipitated DNA samples were
analyzed by real-time PCR for IL-21R promoter or -actin as a control. The
sequences of the primers and TaqMan probes were as follows: IL-21R promoter
forward primer, 5-GGTCCCTAAGAGGGAAGTGTCA-3; reverse primer,
5-GCACCCACTGTCACCAAAGG-3; probe, 5-FAM-CCCGATGGCCCC
AAATGTCTTACTTG-TAMRA-3; -actin forward primer, 5-TCCACCTTC
CAGCAGATGTG-3; reverse primer, 5-GCAACTAAGTCATAGTCCGCC
TAGA-3; and probe, 5-FAM-AGCAGGAGTATGACGAGTCCGGCCC-
TAMRA-3.
RESULTS
IL-21R expression is induced by TCR stimulation. We ini-
tially investigated the regulation of IL-21R expression in hu-
man T cells using real-time PCR. IL-21R mRNA was not
expressed in unstimulated Jurkat or Molt-3 cells, but levels
gradually increased following stimulation with PI (Fig. 1A and
B). IL-21R mRNA levels in primary human peripheral T cells
were also induced by PI (Fig. 1C) or anti-CD3 plus anti-CD28
(Fig. 1D) within 2 h, then declined to a nadir at 16 h, and then
again increased (Fig. 1C and D), reproducibly exhibiting a
biphasic induction pattern. The induction of IL-21R mRNA
expression after T-cell receptor (TCR) stimulation was primar-
ily at the level of transcription, as the transcription inhibitor,
actinomycin D, markedly diminished the inducibility (Fig. 1E).
Interestingly, although the protein synthesis inhibitor, cyclo-
heximide, moderately increased IL-21R mRNA in resting cells,
it almost abolished the induction of IL-21R mRNA upon TCR
activation (Fig. 1E), indicating that de novo protein synthesis is
required for TCR-induced transcription of IL-21R.
Identification of the IL-21R major transcription initiation
site. The human IL21R gene contains nine exons, with exons 1a
and 1b coding for the 5 untranslated region (35). Exons 1a and
1b were defined based on the 5 ends of cDNA clones that have
not been proven to correspond to transcription initiation sites.
We used 5 RACE to identify the IL-21R transcription initia-
tion site(s) in human PB T cells activated with anti-CD3 plus
anti-CD28. In this method, a “RACER RNA oligonucleotide”
was ligated to the 5 end of the mRNA. Three antisense IL21R
gene-specific primers, GSP1, GSP2, and GSP3, targeting dif-
ferent regions of the receptor mRNA (at 805 to 828, 647
to670, and607 to630, respectively), were paired with the
“RACER 5 primer” complementary to the “RACER RNA
oligonucleotide” to amplify the 5 end of the IL-21R mRNA
(Fig. 2A). Since multiple weak PCR products were observed
when using either GSP1 or GSP2, we performed nested PCR
by using the PCR product from the GSP1 amplification paired
with GSP2 and “RACER 5 nested primer” (Fig. 2B, lane 2) or
the PCR product from the GSP2 amplification paired with
GSP3 and “RACER 5 nested primer” (Fig. 2B, lane 3). Each
yielded a major band of approximately 900 bp, but as expected,
the level was slightly higher in the GSP2 reaction (Fig. 2B,
lane 2). Subcloning and sequencing of this PCR product
showed that the major transcription initiation site for IL-21R is
243 bp upstream of the original exon 1a (Fig. 2C) (13 of 19
clones yielded this position, and the other clones had a 5 end
205 nucleotides upstream of exon 1a, which may be a minor
FIG. 2. Mapping of a major human IL-21R transcription initiation
site by 5 RACE. (A) Locations of primers used in the 5 RACE.
IL21R GSPs 1, 2, and 3 are complementary to the regions from 805
to 828, 647 to 670, or 607 to 630, respectively (relative to the
boundary of IL-21R 5 cDNA) (35). RACER 5 primer and RACER
5 nested primer complementary to the RACER RNA oligonucleotide
were provided by the GeneRACER kit. (B) Total RNA was isolated
from human PB T cells treated with 2 g/ml of anti-CD3 plus 1 g/ml
of anti-CD28 antibody for 2 h. The 5 end of IL-21R was PCR ampli-
fied by RACER 5 primer with GSP1 (product 1) or GSP2 (product 2).
The nested PCR was performed by using nested primers and PCR
product 1 (lane 2) and product 2 (lane 3). Lane 1 shows the molecular
weight marker. Arrows indicate the bands cut from the gel for sub-
cloning and sequencing. (C) Partial sequence of the 5 regulatory
region of the IL21R gene showing the major transcription initiation
site (arrow) 243 nucleotides 5 of exon 1a (open box).
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transcription initiation site). Thus, we redefined the boundary
of exon 1 as the major transcription initiation site.
Identification of a DNase I-hypersensitive site approxi-
mately 100 bp 5 of the transcription initiation site. To identify
potential regulatory elements that mediate human IL-21R in-
duction, we examined the sequence flanking the transcription
initiation site for DNase I-hypersensitive sites. We used NdeI,
which cleaves at 7.6 kb and 6.8 kb relative to the transcrip-
tion initiation site (Fig. 3A). Nuclei from untreated or PI-
activated Molt-3 cells were subjected to DNase I hypersensi-
tivity assays. Southern blotting of NdeI-digested genomic DNA
and hybridization with probe 1 revealed a hypersensitive site
approximately 100 bp 5 to the transcription initiation site in
both PI-stimulated and unstimulated cells (Fig. 3B, left panel).
Digestion of DNase I-treated genomic DNA with BglI and
subsequent hybridization with probe 2 revealed the same hyper-
sensitive site (Fig. 3B, right panel). A similarly positioned hyper-
sensitive site was also detected in human primary T cells stimu-
lated with anti-CD3 plus anti-CD28 or not stimulated (Fig. 3C).
The fact that the same DNase I-hypersensitive site was observed
in both unstimulated and stimulated cells indicates that this site is
accessible under either basal or induced conditions.
Recently, a genome-wide mapping technique (GMAT) of
histone H3 acetylation in resting and activated human T cells
FIG. 3. Characterization of a DNase I-hypersensitive site in the human IL21R gene. (A) Schematic showing the location of a DNase
I-hypersensitive site in the human IL21R gene. The thick bars represent the probes; the open box represents exon 1a. The major transcription
initiation site mapped by 5 RACE is indicated by the arrow. (B) Nuclei were isolated from Molt-3 cells cultured for 4 h with or without PI and
then digested with DNase I as indicated. DNA was extracted, digested with either NdeI or BglI, and analyzed on a 0.6% agarose gel. The
hypersensitive site was mapped by hybridizing NdeI-digested DNA with probe 1 (6331 to 6754) and BglI-digested DNA with probe 2 (1051
to 1352). (C) Nuclei isolated from human PB T cells cultured with or without anti-CD3 and anti-CD28 were digested with DNase I. The
hypersensitive site was mapped by hybridizing BglI-digested DNA with probe 2. (D) Acetylation levels of the IL21R gene on chromosome 16 in
resting primary human T cells (upper panel) or anti-CD3 and anti-CD28 antibody-activated (24 h) primary T cells (lower panel) were analyzed
by GMAT. The genome-wide data are posted at the website http://dir.nhlbi.nih.gov/labs/lmi/zhao/epigenome/G&D2005.htm. The retrieved region
includes the promoter and the first intron of the IL21R gene, as indicated by the scheme at the bottom. (E) Nuclei isolated from human PB T cells
treated with anti-CD3 and anti-CD28 for 4 h or not treated were briefly digested with BstEII. The purified genomic DNA was digested to
completion with StuI. The cleavage sites were detected by linker ligation-mediated PCR with the antisense IL-21R GSP. The data were quantified
by PhosphorImager. The intensity of the BstEII band was normalized for the intensity of the StuI band. The bars represent induction of BstEII
accessibility (n-fold) compared with no treatment. Values are means  SEM of results from three experiments. Locations of restriction enzymes
and primers for PCR are shown at the top.
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was established (44). This method combines chromatin immu-
noprecipitation assays using an antibody to K9/K14 diacety-
lated histone H3 and serial analysis of gene expression tech-
nique (SAGE) to generate a GMAT library wherein the
frequency of each SAGE tag reflects the level of histone mod-
ification at the corresponding gene locus. The level of H3
hyperacetylation is correlated with chromatin accessibility of
promoters and regulatory elements. Using the human ge-
nome acetylation database (http://dir.nhlbi.nih.gov/labs/lmi
/zhao/epigenome/G&D2005.htm), we analyzed H3 acetylation
throughout the IL21R gene and found the promoter region
around the DNase I-hypersensitive site was highly acetylated in
activated as well as resting T cells (Fig. 3D). To confirm that
this region is under chromatin structure remodeling upon ac-
tivation, we performed a restriction enzyme accessibility assay,
which has been extensively used to determine subtle cleavages
in nucleosomal structure (8, 12, 53). We briefly digested the
nuclei of human PB T cells with BstEII, which has a cleavage
site at 140 relative to the transcription initiation site. Follow-
ing complete digestion of the purified DNA with StuI (cleav-
age site at 214), which serves as an endogenous control, the
cleavage sites were detected by linker ligation-mediated PCR
with a universal linker primer and a downstream antisense
GSP. Cells treated with anti-CD3 plus anti-CD28 manifested a
twofold increase in BstEII accessibility (Fig. 3E), demonstrat-
ing that the IL-21R promoter is remodeled to a more open
structure.
The TGGGCGmotif in the promoter region is important for
IL-21R expression. To identify the sequences critical for IL-21R
promoter activity, the 2300 to 350 region was cloned in a
luciferase reporter vector. Transient transfection of Molt-3
cells with this construct showed a potent increase in PI-induced
activity (Fig. 4A). Analysis of a series of 5 deletion constructs
revealed that potent reporter activity was present in a construct
extending to 80 but not to 20 (Fig. 4A), indicating a critical
role for the 80 to 20 region in PI-induced IL-21R promoter
activity.
To identify binding sites for the transcription factor(s), we
next performed EMSAs using nested overlapping oligonucle-
otide probes that together span the 101 to 12 region (101
to 72, 81 to 52, 61 to 32, or 41 to 12) and nuclear
extracts from resting or PI-treated human PB T cells. Two
complexes, C1 and C2, were formed only with the 61 to 32
probe (Fig. 4B, lanes 5 and 6). C1 was potently induced after
PI stimulation, whereas C2 was only slightly induced (Fig. 4B,
lanes 5 and 6, and C, lanes 1 and 2). The formation of the
complexes was eliminated by competition with unlabeled wild-
type oligonucleotide (Fig. 4C, lane 3). The “smear-like” DNA-
binding protein complex seen with extracts from resting T cells
(Fig. 4B, lane 5, and C, lane 1) was consistently observed in
extracts isolated from different donors, minimizing the possi-
bility that the smear represents protein degradation. Further-
more, when the same extracts were incubated with an IL-7R
promoter probe spanning an Ets binding motif for GA binding
protein (55), the appropriate band was identified without a
“smear,” indicating that general protein degradation had not
occurred (data not shown).
To further define the factor binding sites, we made a
series of mutant oligonucleotide probes by changing every
three nucleotides within the 61 to 32 region (Fig. 5A)
and incubated these probes with nuclear extracts from PI-
activated human PB T cells. Mutation of either TGG to
GTT (Mut5) or GCG to TAT (Mut6) greatly diminished
DNA-protein complex formation (Fig. 5B, lanes 7 and 8).
FIG. 4. The 80 to 20 region is important for IL-21R promoter
activity in response to TCR activation and forms complexes with nu-
clear factors. (A) Luciferase (Luc) reporter construct schematics are
on the left. These were transfected into Molt-3 cells that were not
stimulated or stimulated with PI. Luciferase activity was normalized
with renilla luciferase activity (relative light units, RLU). Shown are
means  SEM of results from three experiments. (B) Nuclear extracts
from PI-treated (4 h) or untreated human PB T cells were incubated
with the indicated IL-21R promoter probes and subjected to EMSA.
Two DNA-binding protein complexes, C1 and C2, are indicated.
(C) EMSA with the 61 to 32 probe and nuclear extract from
untreated or PI-treated human PB T cells. In lane 3, a 100-fold molar
excess of unlabeled 61 to 32 oligonucleotide was preincubated with
nuclear extract before adding the probe.
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Similar findings were observed in Molt-3 cells (data not
shown).
Consistent with the importance of these complexes, deletion
of the 61 to 32 region from the 80 to 350 construct
greatly decreased PI-induced IL-21R promoter activity in
Molt-3 cells, and when the TGG (Mut5) and GCG (Mut6)
mutations were made in the 80 to 350 construct, the in-
duced IL-21R promoter activity was also decreased (Fig. 5C,
left panel). Because we could not achieve efficient transfection
in human T cells, we transiently transfected these constructs
into primary murine splenic T cells and found activation-in-
duced IL-21R promoter activity (Fig. 5C, right panel) similar
to the findings in Molt-3 cells. These data indicate a critical
role for the TGGGCG region for IL-21R promoter activity.
Identification of Sp1 and Sp3 binding to the GC box in the
IL-21R promoter in vitro. To characterize factor(s) binding to
the TGGGCG region, we used DNA affinity chromatography
(55). PCR-amplified concatemers spanning the entire 61 to
32 region (containing the TGGGCG motif) were biotinyl-
ated and tethered to streptavidin paramagnetic particles. A
parallel control purification was performed in which TGG
GCG was mutated to GTTGCG (Mut5). Nuclear extracts from
PI-activated human PB T cells were separately incubated with
each affinity resin and washed to remove the nonspecific bind-
ing, and eluates were resolved by SDS-PAGE and silver
stained. Several bands were more enriched in the eluate from
wild-type resin than in that from mutant resin. The major band
of approximately 95 kDa that was present only in the wide-type
resin eluate (Fig. 6A) was analyzed by LC-MS and MALDI-
TOF mass spectrometry and identified as Sp1. The p80 band
also contained Sp1 peptides and perhaps represents a degra-
dation product of Sp1. No peptides were detected from the p40
band, so the identity of p40 is completely unclear. The inability
to recover peptides may have been due to protein degradation
or a low abundance of the material.
Sp1 is a sequence-specific zinc finger transcription factor
that recognizes GGGGCGGGGC motifs (GC box) and closely
related sequences (5, 21). Sequence comparison showed that
FIG. 5. Characterization of the TGGGCG motif in the 5 regulatory region of IL-21R responsible for TCR-induced activity. (A) Sequence of
the wild-type (WT) and mutant (Mut) 61 to 32 IL-21R probes used in EMSAs. (B) EMSAs with WT or Mut probes and nuclear extract from
human PB T cells treated with PI for 4 h or not treated. (C) Transient transfection of IL-21R promoter reporter constructs in Molt-3 cells and
mouse splenic T cells. Luciferase (Luc) reporter construct schematics are on the left. Mut5 and Mut6 are shown in panel A. The luciferase
constructs were transfected into Molt-3 cells followed by no stimulation or stimulation with PI or transfected into preactivated mouse splenic
T cells that were then not treated or stimulated with anti-CD3/CD28. Luciferase activity was measured and normalized with Renilla luciferase
activity (relative light units, RLU). Values are means  SEM of results from three experiments.
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the GGGCGGGGC sequence is exactly conserved in the 5-
proximal region in the mouse Il21r gene even though the ad-
jacent nucleotide diverges (Fig. 6B). We confirmed the binding
of recombinant Sp1 protein to the IL-21R promoter by EM-
SAs, and this complex has similar migration to that of complex
C1 from human PB T cells (Fig. 6C, lane 1 versus lane 6).
Addition of anti-Sp1 also decreased the intensity of C1
(Fig. 6C, lane 7) but did not abrogate the complex the way it
did the complex generated with recombinant Sp1 (Fig. 6C,
lane 2), and it had no effect on complex C2 (Fig. 6C, lane 7).
This might relate to a possible modification of Sp1 in the T-cell
extract that might compromise the accessibility of the antibody
to Sp1 or alternatively may represent the binding of a factor in
addition to Sp1. We therefore tested the effect of antibodies to
other Sp family proteins, as Sp3 and Sp4 act through the same
GC (GGGGCGGGG) box while Sp2 mainly acts through a GT
box (GGTGTGGGG) (4, 7). An antibody to Sp3 abolished the
C2 complex (Fig. 6C, lane 9), analogous to its elimination of
the complex formed with recombinant Sp3 (Fig. 6C, lane 4
versus lane 3). The recombinant Sp3 contains only the 100-kDa
isoform, which may explain why its migration was different
from C2, which potentially contains the 60- and 58-kDa iso-
forms of Sp3. As expected, when an unlabeled Sp1 consensus
oligonucleotide containing the GC box was added at 25-, 50-,
or 100-fold molar excess, the formation of both C1 and C2 was
partially reduced (Fig. 6C, lanes 11 to 13). Antibodies to the
other Sp family proteins, Sp2 and Sp4, had no effect (Fig. 6C,
lanes 8 and 10). This is consistent with Sp4 being more specific
for the brain (7) and the fact that in vitro-translated Sp2 could
not bind to the IL-21R promoter (data not shown), making it
less likely that Sp2 or Sp4 is involved in the regulation of
IL-21R.
We next examined whether the expression levels of Sp1 and
Sp3 in primary T cells were changed upon TCR stimulation.
FIG. 6. Sp1 and Sp3 bind to the GC motif in the IL-21R promoter in vitro. (A) Proteins purified by DNA affinity chromatography. Nuclear
extracts from PI-stimulated (4 h) human PB T cells were subjected to DNA affinity chromatography. Eluates from WT or mutant (Mut5, as in
Fig. 5A) DNA-conjugated beads were resolved by SDS-PAGE and silver stained. LC-MS and MALDI-TOF mass spectrometry were conducted
on the 95-, 80-, and 40-kDa bands (arrows). The 95-kDa band is Sp1. (B) Sequence comparison of human and mouse IL-21R promoter-proximal
region showed a conserved GGGCGGGGC motif. (C) EMSA using WT probe and recombinant Sp1, Sp3, or nuclear extracts (NE) from human
PB T cells treated with PI or not treated. Antibodies to Sp1, Sp2, Sp3, Sp4, or unlabeled oligonucleotides containing the Sp1 consensus sequence
at 25-, 50-, or 100-fold molar excess were preincubated with nuclear extract before adding WT probe, as indicated. (D) Nuclear extracts (15 g)
from anti-CD3-plus-anti-CD28-activated human PB T cells or mouse splenic T cells were blotted with anti-Sp1 or -tubulin (control). (E) Nuclear
extracts (15 g) were blotted with anti-Sp3 or -tubulin.
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Interestingly, in human PB T cells, the basal expression of Sp1
was variable among different donors. In those donors with low
basal expression, Sp1 was potently induced after stimulation
with anti-CD3 plus anti-CD28 (Fig. 6D, donor 1), whereas in
other donors where Sp1 was expressed at a high level in resting
cells, no inducibility was observed (Fig. 6D, donor 2). It is
possible that the altered basal levels of Sp1 expression might
reflect recent exposure of some donors to antigenic stimuli.
Consistent with this, the level of Sp1 was low in naı¨ve resting
mouse splenic T cells but consistently induced after TCR ac-
tivation (Fig. 6D). Our data thus indicated that Sp1 bound to
the IL-21R promoter in vitro and that TCR stimulation aug-
mented levels of Sp1. In contrast, the expression level of Sp3
was relatively stable upon TCR activation, and even in the
donors with induced Sp1 expression, no inducibility of Sp3 was
observed (Fig. 6E).
Suppression of TCR-mediated IL-21R induction by siSp1.
To investigate the role of Sp1 and Sp3 in vivo for TCR-
induced IL21R gene regulation, we used synthetic small
interfering RNAs (21-nucleotide duplex siRNAs). As a con-
trol, we used an siRNA that, based on bioinformatic algo-
rithms, was designed to have more than four mismatches
with other known human genes. We transfected 25, 50, 100,
150, or 200 nM siSp1 or siSp3 into human primary T cells
and found that 100 nM provided an optimal silencing effect
by measuring the Sp1 or Sp3 mRNA levels using quantita-
tive real-time PCR (data not shown), and we used this dose
in subsequent experiments. In human PB T cells, when the
Sp1 expression level was effectively silenced by siRNA trans-
fection (Fig. 7B), the level of TCR-induced IL-21R expres-
sion was diminished by over 50% (Fig. 7A). However, when
the expression level of Sp3 was effectively silenced by siSp3
(Fig. 7C), the TCR-induced IL-21R expression was at most
minimally reduced. Moreover, the combination of siSp3 and
siSp1 did not decrease the expression of IL-21R more than
transfection of only siSp1 (Fig. 7A). The control siRNA did
not affect Sp1 (Fig. 7B), Sp3 (Fig. 7C), or IL-21R (Fig. 7A) ex-
pression. These results demonstrate that although both Sp1 and
Sp3 bind to the IL-21R promoter, Sp1 plays a more critical role in
regulating IL-21R expression in human T cells.
FIG. 7. Binding of Sp1 to the IL-21R promoter is essential for TCR-induced IL-21R expression. Suppression of IL-21R expression in human
primary T cells by siRNA targeting of Sp1 is also shown. Human PB T cells were transfected with 100 nM siRNAs along with pEYFP-N1 and were
cultured for 36 h. YFP cells were sorted and stimulated with anti-CD3 and anti-CD28 for 2 h. Total RNA was extracted and analyzed for IL-21R
(A), Sp1 (B), and Sp3 (C) expression by quantitative real-time PCR. IL-21R, Sp1, and Sp3 expressions were normalized to the level of expression
of 18S rRNA. For each sample, the bar represents the induction (n-fold) compared to no TCR activation. Values are means  SEM of results
from three experiments. (D) In vivo binding of Sp1 to the IL-21R promoter in human primary T cells by chromatin immunoprecipitation. Human
PB T cells were cultured with or without anti-CD3 and anti-CD28 for 2 h. Formaldehyde-cross-linked chromatin was immunoprecipitated with
preimmune rabbit serum or with anti-Sp1. Real-time PCR was performed to quantitate the DNA fragment containing the Sp1 binding site in the
IL-21R promoter. -Actin was a control. Values are means  SEM of results from three experiments.
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Sp1 binds in vivo to the IL-21R promoter. To determine if
Sp1 bound to the IL-21R promoter in human primary T cells
in vivo, we performed ChIP assays using an antibody to Sp1.
Real-time PCR was used to quantitate the abundance of DNA
fragment spanning the IL-21R promoter with Sp1 binding
sites, with the -actin gene as an indicator of the nonspecific
background after immunoprecipitation. Upon TCR activation,
the Sp1 antibody reproducibly resulted in a 2- to 2.5-fold in-
crease in the IL-21R promoter ChIP signal compared to that
seen with controls (Fig. 7D). These results demonstrate that
Sp1 binds to the IL-21R promoter in vivo and that the binding
increases after TCR activation.
TCR-induced IL-21R expression depends on the dephos-
phorylation of Sp1. Posttranslational modification of Sp1 is
known to regulate its transcriptional activity. For example,
lipopolysaccharide treatment reduced Sp1 DNA-binding activ-
ity and transcriptional activation by dephosphorylation of Sp1
at serine and threonine residues (56). In addition, it was re-
ported that in human T lymphocytes treated with anti-CD2
plus anti-CD28, Sp1 was dephosphorylated, correlating with
cell cycle progression. The dephosphorylation of Sp1, which
was mediated by protein phosphatase 2A (PP2A), increased its
transcriptional activity in a reporter assay in Kit225 cells (22).
We thus examined the effect of calyculin A, a potent inhibitor
of both PP2A and protein phosphatase 1 (PP1) that specifically
inhibits dephosphorylation at serine/threonine residues (43),
on TCR-induced IL-21R expression. When 10 nM calyculin A
was incubated with human PB T cells stimulated with anti-CD3
plus anti-CD28 for 2 h, it blocked the IL-21R mRNA induction
(Fig. 8A) without affecting viability or expression of 18S rRNA
(data not shown). A second phosphatase inhibitor, okadaic
acid, which binds to the catalytic subunits of PP1 and PP2A
FIG. 8. Dephosphorylation of Sp1 is essential for TCR activation-induced IL-21R expression. Human PB T cells were not stimulated or
stimulated with anti-CD3 and anti-CD28 for 2 h. Half of the cells were coincubated with 10 nM calyculin A or 0.8 M okadaic acid. Total RNA
and nuclear extract were isolated from these cells. (A) Suppression of TCR-induced IL-21R mRNA expression by calyculin A or okadaic acid
treatment. Total RNA was transcribed to first-strand cDNA, and IL-21R mRNA levels were quantitated by real-time PCR and normalized to the
level of 18S rRNA. The bar represents the induction (n-fold) compared with no treatment. Values are means  SEM of results from three
experiments. (B) Calyculin A or okadaic acid treatment diminished the Sp1 DNA-binding activity. Nuclear extracts were incubated with the 61
to 32 probe of IL-21R promoter and subjected to EMSA. Different donors were used by the calyculin A and okadaic acid experiments,
presumably explaining the difference in the levels of Sp1. (C) Calyculin A or okadaic acid treatment inhibited Sp1 dephosphorylation. Fifteen
micrograms of the nuclear extract was subjected to SDS-PAGE on 8% Novex Tris-glycine gel or 8% NuPAGE Tris-acetate gel, transferred to an
Immobilon-P membrane, and blotted with anti-Sp1 or -tubulin.
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(with a 200-fold-higher affinity for PP2A) (22), caused a similar
reduction of TCR-induced IL-21R expression (Fig. 8A). By
EMSA, the DNA-binding activity of Sp1 was decreased by
calyculin A or okadaic acid treatment in T cells activated with
anti-CD3 plus anti-CD28 (Fig. 8B, lane 4 versus lane 3 and
lane 8 versus lane 7). The decrease in DNA-binding activity did
not result from protein degradation after cytotoxic calyculin A
treatment, as Sp1 protein expression was if anything somewhat
increased after calyculin A treatment, as detected by Western
blotting (Fig. 8C, lane 2 versus lane 1 and lane 4 versus lane 3).
By Western blotting, two Sp1 bands were detected in resting
T cells (Fig. 8C, lane 1), with the lower-molecular-weight form
most likely arising from dephosphorylation, given the increase
in the upper band after calyculin A treatment (Fig. 8C, lane 2).
TCR stimulation augmented Sp1 with a relative increase in the
lower dephosphorylated band (Fig. 8C, lane 3), and the addi-
tion of calyculin A again increased the higher-molecular-
weight phosphorylated form (Fig. 8C, lane 4). Similar effects
on Sp1 expression level were observed in okadaic acid-treated
T cells (Fig. 8C). Together, these results indicate that TCR
stimulation induces Sp1 with a relative increase in the dephos-
phorylated form, and the dephosphorylation of Sp1 may be
required for IL-21R promoter activity.
DISCUSSION
We have demonstrated that TCR-induced IL-21R expres-
sion is regulated at the level of transcription in human T cells
and depends on the synthesis of new proteins. Interestingly,
the induction pattern is biphasic in primary T cells. This pat-
tern may be due to the involvement of different factors that
regulate early/late induction. In the early induction phase, IL-
21R mRNA induction requires the synthesis of new or activa-
tion of preexisting transcription factors. We hypothesize that
the late induction of IL21R gene expression may result from
cytokines produced by activated T cells. For example, IL-21 is
known to up-regulate expression of its own receptor (57).
In examining the molecular mechanism underlying the tran-
scriptional regulation of the IL21R gene, we found that Sp1
binds to a GC-rich motif in the proximal promoter and medi-
ates IL-21R induction in activated human T cells. Sp1 is known
to activate many vital genes, including genes involved in cell
growth and development (5, 15, 21), and homozygous deletion
of Sp1 in mice causes severe lethal embryonic malformation
(30). Classically, Sp1 was viewed as a constitutive transcription
factor that regulates the basal expression of many cellular
genes (7, 14). However, it has now been found to be involved
in tissue-specific gene expression and in the control of tran-
scription following different stimuli (3, 40, 51).
In the immune system, Sp1 has been reported to control the
expression of genes that mediate important cellular functions.
For example, Sp1 regulates the expression of genes encoding
IL-2R (26), TCR V (19), and FasL (54) and plays a critical
role in regulating the division of T lymphocytes after costimu-
lation with anti-CD2 and anti-CD28 (22). We now show that
Sp1 plays an essential role in regulating TCR-induced IL-21R
expression. Mutation of the Sp1 binding sites in the IL-21R
proximal promoter region diminished PI-induced reporter ac-
tivity. Strikingly, Sp1 expression was significantly increased in
primary T cells after TCR stimulation. The TCR-induced aug-
mentation of Sp1 transcriptional activity correlated with induc-
tion of IL-21R mRNA, and transfection of Sp1 siRNAs into
primary human T cells significantly decreased TCR-induced
IL-21R mRNA expression. Unexpectedly, however, Sp1 ex-
pression is only slightly increased 2 h after TCR activation,
while IL-21R mRNA levels were highly induced at this time
point. We therefore hypothesized that posttranslational mod-
ification of Sp1 might play a critical role for IL-21R gene
expression. Depending on cell type and stimuli, phosphoryla-
tion of Sp1 has been reported to either increase (41, 45) or
decrease (1, 23, 32, 58) Sp1 transcriptional activity. We thus
examined the effect of the phosphatase inhibitors calyculin A
and okadaic acid, which inhibit PP1 and PP2A activity, and
found that they decreased IL-21R expression. Moreover, the
phosphatase inhibitors increased the phosphorylation of Sp1
and correspondingly decreased Sp1 DNA-binding activity for
the IL-21R promoter. These results suggest that posttransla-
tional modification of Sp1 is critical for TCR-induced IL-21R
expression.
Sp1 has been reported to exert its transcriptional activation
with the help of other comodulators or cofactors, such as
NF-	B (20), STAT proteins (6, 28), Smad family factors (33),
Egr family factors (26, 50), NFAT family proteins (54), or
other members of the Sp family (9, 46). Complex C2, as de-
tected in EMSA, appears to represent Sp3, since anti-Sp3
diminished the formation of C2. However, the DNA-binding
activity of complex C2 was only slightly induced by PI activa-
tion, in contrast to Sp1, whose binding activity was markedly
induced. In addition, siSp3 had little effect on TCR-induced
IL-21R expression, and the cotransfection of siSp1 and siSp3
was not more potent than siSp1 transfection alone. Thus, un-
like Sp1, Sp3 plays only a minor role in regulating IL-21R
repression. So far, we do not yet have definitive data that
support factors other than Sp1 as critically contributing to the
regulation of IL-21R. Since PI activation is associated with
protein kinase C activation and calcium/calcineurin pathway, it
is conceivable that other factors, such as AP-1, NF-	B, or
NFAT (10, 13, 42, 49), might be involved in IL-21R regulation,
an area for future investigation.
Taken together, our results reveal that Sp1 is indeed a critical
regulator of IL21R gene expression, a finding with implications as
to how the expression of this critical receptor can be controlled.
Moreover, the observation that Sp1 is potently induced and de-
phosphorylated in response to anti-CD3 plus anti-CD28 has
much broader implications for the regulation of Sp1-dependent
genes in antigen-activated T cells. Further studies are needed to
clarify how TCR activation induces the dephosphorylation of Sp1
and to identify the relevant target residues. Such studies will not
only further clarify the basis for IL-21R regulation but also help
us to understand how Sp1-regulated genes in general are broadly
controlled in the immune system.
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